Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO

Tyra Biosciences, Inc.

2022-Q3 EPS reported -$3.63

Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.
Net loss of $6.6M ($0.72/sh) for Q3 2021 vs $2.3M ($1.47/sh) in Q3 2020.
Nominated TYRA-200 (FGFR2 inhibitor) for clinical development; IND expected 2H 2022.
Appointed Esther van den Boom CFO, John Healy GC, Allison Kemner VP, Rehan Verjee to board.
R&D expenses $5.5M (up from $1.9M) driven by pipeline advancement and personnel costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.